Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Retrospective analysis of R-CDOP efficacy and safety in frail patients with DLBCL compared to R-CHOP in fit patients

View Full Paper
Ask AI
Bookmark
Share

Authors

CTChuan TianRGRui GuoFLFengshuo Lan

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows R-CDOP has similar DFS but lower OS compared to R-CHOP in DLBCL patients, suggesting safety of PLD substitution.

Key Points

  • To compare the efficacy and safety of R-CDOP versus R-CHOP in frail patients with DLBCL.
  • Retrospective analysis of DLBCL patients receiving R-CHOP or R-CDOP at Stony Brook University Hospital
  • Evaluation of patient demographics, overall survival, disease free survival, and adverse events
  • Statistical analysis using log-rank test for survival and two tailed t-tests for quantitative variables
  • R-CDOP group had lower overall survival (5-year OS 53% vs 94% for R-CHOP)
  • No significant increase in adverse events or grade ≥3 toxicities in R-CDOP compared to R-CHOP
  • 5-year disease free survival was comparable (75% for R-CDOP vs 88% for R-CHOP)

Cite This Study

Tian et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e286https://doi.org/10.1182/blood-2025-7205
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study2025
  2. 2Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis2022 · 4 citations
  3. 3Tolerability and long-term survival of fragile or older patients with diffuse large B cell lymphoma (DLBCL) not otherwise specified by R-CDOP2025
  4. 4Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma2025
  5. 5Long-term outcomes, survival predictors and up-front treatment patterns in 568 elderly diffuse large b-cell lymphoma patients from LATAM: Is R-CHOP still the first choice for treating patients older than 60 years?2025